Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4753560 | 1.00 | TSHR (0.49) | TSHRTHRBPOLBAPEX1HTT | |
| Alcohol SCHEMBL4941627 | 0.92 | TSHR (0.53) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL37108 | 0.92 | TSHR (0.56) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL25235967 | 0.92 | TSHR (0.56) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL14060478 | 0.91 | TSHR (0.54) | TSHRTHRBPOLBAPEX1HTT | |
| Hydrogen Sulfide SCHEMBL329936 | 0.91 | TSHR (0.54) | TSHRTHRBPOLBAPEX1HTT | |
| Methyl Alcohol SCHEMBL28830046 | 0.91 | TSHR (0.54) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL29094388 | 0.90 | TSHR (0.58) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL16115101 | 0.90 | TSHR (0.54) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL222521 | 0.88 | TSHR (0.51) | TSHRTHRBPOLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4263868-A1 | NANOARRAYS AND METHODS OF USE THEREOF | Singular Genomics Systems, Inc. (US) | 2023-10-25 | — | — | EP | claimed |
| WO-2022192671-A1 | NANOARRAYS AND METHODS OF USE THEREOF | Singular Genomics Systems, Inc. (US) | 2022-09-15 | — | — | WO | claimed |
| WO-2008149375-A1 | IMPROVED ORGANOSILICON COMPOUNDS | RANKA, SEEMA, AJAY (IN) | 2008-12-11 | — | — | WO | claimed |
| US-20080009644-A1 | Organosilicon Compounds | ZYDEX INDUSTRIES | 2008-01-10 | — | — | US | claimed |
| US-20230399692-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-12-14 | — | — | US | disclosed |
| EP-4263868-A1 | NANOARRAYS AND METHODS OF USE THEREOF | Singular Genomics Systems, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11795505-B2 | Nucleic acid delivery scaffolds | Singular Genomics Systems, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230287491-A1 | NUCLEIC ACID DELIVERY SCAFFOLDS | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-09-14 | — | — | US | disclosed |
| US-20230203579-A1 | NANOARRAYS AND METHODS OF USE THEREOF | FIRST-CITIZENS BANK & TRUST COMPANY | 2023-06-29 | — | — | US | disclosed |
| WO-2022192671-A1 | NANOARRAYS AND METHODS OF USE THEREOF | Singular Genomics Systems, Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-7553983-B2 | Organosilicon compounds | ZYDEX INDUSTRIES (IN) | 2009-06-30 | — | — | US | disclosed |
| US-20080009644-A1 | Organosilicon Compounds | ZYDEX INDUSTRIES | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009644-A1 | Organosilicon Compounds | CUL1, CUL3, MGAM | TSHR 4731/4885THRB 4707/4885POLB 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.